Background: Previously we reported the use of a monoclonal antibody-based (HP10) antigen (Ag) detection lateral flow assay (LFA) for the diagnosis of extraparenchymal neurocysticercosis (EP-NCC). The assay performed well when used with cerebrospinal fluid (CSF) samples but not with their paired serum samples, due to false-positive reactions in some known negative control cases.
Introduction
The zoonotic tapeworm Taenia solium, the causal agent of lifethreatening human neurocysticercosis (NCC), constitutes an increasingly major health risk, with profound socio-economic impacts. It is prevalent in Asia, Africa and Latin American. Importantly, NCC is estimated to be one of the most frequent parasite infections of the human brain and is responsible for 30% of preventable cases of epilepsy and 2.8×10 6 disabilityadjusted life years. 1 The related parasite Taenia saginata passes its metacestode stage only in cattle. Control is a major, longterm and expensive goal, but whatever the control strategy, be it drugs, education, sanitation or other public health measures, the first step is the identification of rural endemic populations, the majority of which do not have ready access to effective but sophisticated imaging diagnostic technologies. Hence the World Health Organization has emphasized the need for an economic and reliable 'on site or point of contact' diagnosis of cysticercosis in rural cysticercosis 'endemic' communities.
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Detection of secreted metacestode glycoproteins constitutes proof of a viable infection, using, for example, the monoclonal antibody-based HP10 antigen enzyme-linked immunosorbent assay (HP10 Ag-ELISA), which has been successfully used for the diagnosis of bovine cysticercosis and for the diagnosis and followup of extraparenchymal (EP), but not parenchymal, NCC.
3-5
Recently the HP10 Ag-ELISA was developed into a lateral flow assay format (HP10 Ag-LFA), 5, 6 and when tested with cerebral spinal fluid (CSF) samples from clinically characterized EP-NCC, there was good agreement between the HP10 Ag-ELISA and the HP10 Ag-LFA. When the corresponding paired serum samples were tested, however, some of the control sera gave an unexplained positive result (our unpublished observations).
We now report the development of a modified HP10 Ag-LFA that permits the diagnosis of human and bovine cysticercosis in the absence of false positives with normal serum samples, thereby providing a field test for the rapid identification of endemic foci of human and bovine cysticercosis.
Materials and methods

Serum samples
Serum samples were taken from 18 patients with confirmed NCC and from 14 control neurological patients diagnosed as NCC negative by neurologists and neurosurgeons at five general hospitals in Cuenca, Ecuador. The HP10 Ag-ELISA results for the samples, together with the clinical and ethical details of the study are as previously described.
5 Bovine serum samples were derived from nine calves 4, 12, 13 and 16 weeks after oral infection with T. saginata eggs, at which points they were slaughtered to verify active infection, and five uninfected control animals.
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HP10 Ag-ELISA
Both control and experimental CSF and human serum samples were assayed in the HP10 Ag-ELISA. 3 The optical density (OD) at 450 nm was recorded and the values presented are the mean of duplicate samples minus the blank and with a variation of ≤10%. Sera from controls and cases of bovine cysticercosis were similarly analysed ( Table 2 ). The mean and standard deviation (SD) for the 14 negative control sera samples in the HP10 Ag-ELISA was 0.015±0.0106, thus giving the very low cut-off value of 0.063 (calculated as mean+3 SD) and permitting the identification of a low cyst burden. An OD≥0.2 was defined as the operational cut-off value for serum samples.
HP10 Ag-LFA
Serum samples were processed as previously described, 5,6 with the following modification: serum (50 μl) was mixed with 5% sodium deoxycholate (NaDOC) containing 5 mM dithiothreitol (DTT) and 50 mM Tris-HCl pH 8.3 (30 μl). After 10 min the sample was added to the LFA cassette and then washed through with 2% NaDOC in 50 mM NaCl and 50 mM Tris-HCl pH 8.3. The procedure takes just 10 min between the application of serum samples to the cassettes and reading the result.
Results and discussion
Using the original HP10 Ag-LFA, 5 4 of 14 of the negative human serum samples and 2 of 5 negative bovine samples gave falsepositive reactions that were abolished by pretreatment of the serum with NaDOC/DTT. None of the clearly positive samples were affected by the pretreatment. Thus application of the HP10 Ag-LFA to serum samples is now feasible.
The modification was based on the hypothesis that false positives were the result of low-affinity, cross-reacting immunoglobulin M (IgM) antibodies. It is known that antibodyantigen interaction is less avid in the detergent NaDOC than in non-ionic detergents 7 and that the IgM molecule is highly sensitive to reduction. 8 We tested the impact of NaDOC and the reducing agent DTT in the LFA system using control bovine serum that gave a false-positive result using the original system (Figure 1a) . In the presence of NaDOC, the control serum was still positive (Figure 1b) , but marginally less. In contrast, inclusion of DTT, with (Figure 1d) or without (Figure 1c ) NaDOC, abolished the false positivity, without an impact on genuinely HP10-positive serum samples (Figure 1e ). Thus the conditions for the LFA were modified to include both NaDOC and DTT.
Using the new LFA conditions we tested the paired serum samples from the previous study, where the LFA testing was restricted to CSF, but the HP10 Ag-ELISA testing was done with both CSF and serum samples. 5 The results using serum from controls and proven cases of NCC are presented in Table 1 , which also includes the previously reported HP10 Ag-ELISA data for comparison of HP10 Ag-ELISA and the modified HP10 Ag-LFA. Sera from controls and cases of bovine cysticercosis were similarly analysed ( Table 2 ). As can be seen, there was good agreement between the LFA and ELISA for both bovine and human cysticercosis, with only marginally positive HP10 Ag-ELISA samples (OD≤0.3) being negative in the HP10 Ag-LFA (e.g., sample 10, Table 1 ).
As the HP10 Ag assay reliably detects EP-NCC but not parenchymal NCC 4,5 (Table 1) , the assay has limits for the general diagnosis of NCC at the level of the individual patient. However, measuring HP10 Ag in serum could be usefully employed for preliminary epidemiological surveys in potentially cysticercosis-endemic rural populations and any positive result would be of obvious clinical concern. Thus the identification of positive sera, indicative of EP-NCC, would identify a community with endemic transmission of cysticercosis and justify public health and medical interventions and is particularly relevant to plans for the control of schistosomiasis through the indiscriminate dosing of entire African populations with anti-helminthic drugs, including praziquantel. 9 Such treatment of populations co-infected with T. solium NCC would be predicted to increase the inflammation around the cyst, thereby provoking severe side effects. 10 Thus prior screening for cysticercosis/NCC, ideally including antibody and antigen detection, would be advisable prior the commencement of mass dosing of rural African populations with praziquantel. Costs would be comparable with other similar screening methods. Similarly, the HP10 Ag-LFA would be useful for the identification of bovine cysticercosis at the field level, certainly on the herd level, as cysticercosis in cattle is known to be overdispersed.
Conclusions
A simple modification to the HP10 Ag-LFA to detect the T. soliumand T. saginata-secreted metacestode HP10 antigen in serum has been developed. The HP10 Ag-LFA should provide a useful tool for identification at field level of rural NCC and bovine cysticercosis foci as a prelude to further control measures. 
